Phase 3 Clinical Trials With Primary Completion Dates in October 2019
This is a list of Phase 3 trials with primary completion dates in October 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| BYSI | BeyondSpring, Inc. | 2019-10-01 | Phase 3 | NCT02504489 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC |
| CPRX | Catalyst Pharmaceuticals, Inc. | 2019-10-01 | Phase 3 | NCT03304054 | Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG |
| FOLD | Amicus Therapeutics, Inc. | 2019-10-01 | Phase 3 | NCT02194985 | Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease |
| GBT | Global Blood Therapeutics, Inc. | 2019-10-01 | Phase 3 | NCT03036813 | Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) |
| ITRM | Iterum Therapeutics plc | 2019-10-01 | Phase 3 | NCT03358576 | Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI) |
| ITRM | Iterum Therapeutics plc | 2019-10-01 | Phase 3 | NCT03357614 | Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults |
| ITRM | Iterum Therapeutics plc | 2019-10-01 | Phase 3 | NCT03354598 | Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women |
| SNY | Sanofi | 2019-10-01 | Phase 3 | NCT03965962 | Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults |
| SNY | Sanofi | 2019-10-01 | Phase 3 | NCT02992418 | Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects |
| SUPN | Supernus Pharmaceuticals, Inc. | 2019-10-01 | Phase 3 | NCT02618408 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) |
| ZLAB | Zai Lab Limited | 2019-10-01 | Phase 3 | NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer |